These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16303215)

  • 41. Responses after one dose of a monovalent influenza A (H1N1) 2009 inactivated vaccine in Chinese population--a practical observation.
    Sun F; Zhang Y; Tian D; Zheng M; Liu L; Zhang R; Dai Z; Chen J; Li T; Lu H
    Vaccine; 2011 Sep; 29(38):6527-31. PubMed ID: 21767595
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial.
    Chiu SS; Chan KH; Tu W; Lau YL; Peiris JS
    Vaccine; 2009 Jul; 27(35):4834-9. PubMed ID: 19523908
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
    Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
    Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunity to influenza in older adults with chronic obstructive pulmonary disease.
    Gorse GJ; O'Connor TZ; Newman FK; Mandava MD; Mendelman PM; Wittes J; Peduzzi PN
    J Infect Dis; 2004 Jul; 190(1):11-9. PubMed ID: 15195238
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
    Avila Aguero ML; Soriano-Fallas A; Umaña-Sauma MA; Ulloa-Gutierrez R; Arnoux S
    Medicina (B Aires); 2007; 67(4):351-9. PubMed ID: 17891930
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of one- and two-dose regimens of influenza vaccine for elderly men.
    Levine M; Beattie BL; McLean DM
    CMAJ; 1987 Oct; 137(8):722-6. PubMed ID: 3651943
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epidermal DNA vaccine for influenza is immunogenic in humans.
    Drape RJ; Macklin MD; Barr LJ; Jones S; Haynes JR; Dean HJ
    Vaccine; 2006 May; 24(21):4475-81. PubMed ID: 16150518
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
    Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y
    Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influenza vaccination in adults with asthma: safety of an inactivated trivalent influenza vaccine.
    Kmiecik T; Arnoux S; Kobryn A; Gorski P
    J Asthma; 2007 Dec; 44(10):817-22. PubMed ID: 18097856
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Trivalent inactivated subunit influenza vaccine Influvac: 25-Year experience of safety and immunogenicity.
    Giezeman KM; Nauta J; de Bruijn IA; Palache AM
    Vaccine; 2009 Apr; 27(18):2414-7. PubMed ID: 19368782
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
    Ashkenazi S; Vertruyen A; Arístegui J; Esposito S; McKeith DD; Klemola T; Biolek J; Kühr J; Bujnowski T; Desgrandchamps D; Cheng SM; Skinner J; Gruber WC; Forrest BD;
    Pediatr Infect Dis J; 2006 Oct; 25(10):870-9. PubMed ID: 17006279
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.
    Szymczakiewicz-Multanowska A; Groth N; Bugarini R; Lattanzi M; Casula D; Hilbert A; Tsai T; Podda A
    J Infect Dis; 2009 Sep; 200(6):841-8. PubMed ID: 19673651
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial.
    Cools HJ; Gussekloo J; Remmerswaal JE; Remarque EJ; Kroes AC
    J Med Virol; 2009 May; 81(5):908-14. PubMed ID: 19319953
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.
    Langley JM; Sales V; McGeer A; Guasparini R; Predy G; Meekison W; Li M; Capellan J; Wang E
    Vaccine; 2009 Sep; 27(42):5913-9. PubMed ID: 19651171
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults.
    Gorse GJ; Falsey AR; Ozol-Godfrey A; Landolfi V; Tsang PH
    Vaccine; 2015 Feb; 33(9):1151-9. PubMed ID: 25613721
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults.
    Cook IF; Barr I; Hartel G; Pond D; Hampson AW
    Vaccine; 2006 Mar; 24(13):2395-402. PubMed ID: 16406171
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial.
    Beran J; Vesikari T; Wertzova V; Karvonen A; Honegr K; Lindblad N; Van Belle P; Peeters M; Innis BL; Devaster JM
    J Infect Dis; 2009 Dec; 200(12):1861-9. PubMed ID: 19909082
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults.
    McNeil SA; Noya F; Dionne M; Predy G; Meekison W; Ojah C; Ferro S; Mills EL; Langley JM; Halperin SA
    Vaccine; 2007 Apr; 25(17):3464-74. PubMed ID: 17270320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.